PTC Therapeutics Q1 net income $866.6M on Novartis deal; guides FY revenue $650-800M

PTC THERAPEUTICS, INC.

2025-Q1 EPS reported $10.04 revenue$1,176,096,000

Net income $866.6M vs loss $91.6M YoY, driven by $986.2M upfront from Novartis PTC518 license deal.
Total net product & royalty revenue $189.9M; DMD franchise (Translarna+Emflaza) $134M, down YoY.
Cash, equivalents & marketable securities $2.027B as of March 31, 2025, up from $1.14B at Dec 31, 2024.
Positive CHMP opinion for Sephience (sepiapterin) in PKU; NDA under FDA review with PDUFA July 29, 2025.
PTC518 Phase 2 PIVOT-HD met primary endpoint of dose-dependent blood HTT lowering; plans to discuss accelerated approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.